CA2934025C - Benzoxazinone derivatives for treatment of skin diseases - Google Patents

Benzoxazinone derivatives for treatment of skin diseases Download PDF

Info

Publication number
CA2934025C
CA2934025C CA2934025A CA2934025A CA2934025C CA 2934025 C CA2934025 C CA 2934025C CA 2934025 A CA2934025 A CA 2934025A CA 2934025 A CA2934025 A CA 2934025A CA 2934025 C CA2934025 C CA 2934025C
Authority
CA
Canada
Prior art keywords
skin disease
klk7
treatment
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2934025A
Other languages
English (en)
French (fr)
Other versions
CA2934025A1 (en
Inventor
Fredrik Wagberg
Goran Leonardsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sixera Pharma AB
Original Assignee
Sixera Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sixera Pharma AB filed Critical Sixera Pharma AB
Publication of CA2934025A1 publication Critical patent/CA2934025A1/en
Application granted granted Critical
Publication of CA2934025C publication Critical patent/CA2934025C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2934025A 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases Active CA2934025C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1430003 2014-01-23
SE1430003-2 2014-01-23
PCT/SE2015/050062 WO2015112081A1 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Publications (2)

Publication Number Publication Date
CA2934025A1 CA2934025A1 (en) 2015-07-30
CA2934025C true CA2934025C (en) 2022-06-07

Family

ID=53681747

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934025A Active CA2934025C (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Country Status (18)

Country Link
US (2) US9695194B2 (enExample)
EP (1) EP3097085B1 (enExample)
JP (1) JP6448651B2 (enExample)
CN (1) CN106132941B (enExample)
AU (1) AU2015209761B2 (enExample)
CA (1) CA2934025C (enExample)
CY (1) CY1123477T1 (enExample)
DK (1) DK3097085T3 (enExample)
ES (1) ES2820868T3 (enExample)
HR (1) HRP20201500T1 (enExample)
HU (1) HUE051296T2 (enExample)
LT (1) LT3097085T (enExample)
PL (1) PL3097085T3 (enExample)
PT (1) PT3097085T (enExample)
RS (1) RS60830B1 (enExample)
SI (1) SI3097085T1 (enExample)
SM (1) SMT202000557T1 (enExample)
WO (1) WO2015112081A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3097085T1 (sl) * 2014-01-23 2020-11-30 Sixera Pharma Ab Derivati benzoksazinona za zdravljenje kožnih bolezni
US10306885B2 (en) 2015-05-13 2019-06-04 Nihon Nohyaku Co., Ltd. Anthranilic acid ester compound or salt thereof, agricultural and horticultural microbicide comprising the compound, and method for using the microbicide
WO2017123401A1 (en) * 2016-01-13 2017-07-20 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
WO2018232300A1 (en) 2017-06-16 2018-12-20 Azitra Inc Compositions and methods for treatment of netherton syndrome with lekti expressing recombinant microbes
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
PH12022550646A1 (en) 2019-09-18 2023-04-03 Genentech Inc Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
ES3053975T3 (en) * 2019-10-01 2026-01-28 Molecular Skin Therapeutics Inc Benzoxazinone compounds as klk5/7 dual inhibitors
GB202001447D0 (en) * 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
BR102020009679A2 (pt) 2020-05-14 2021-11-23 Fundação Universidade Federal Do Abc - Ufabc Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑
WO2022253911A1 (en) 2021-06-01 2022-12-08 Sixera Pharma Ab Oil-in-water emulsion of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,l-benzoxazin-4-one

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB115399A (en) * 1917-03-28 1918-04-29 Reginald Guley Lewis Improved Delivery mechanism for Coin-freed Apparatus and the like.
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
AU2826099A (en) * 1998-03-24 1999-10-18 Novo Nordisk A/S Heterocyclic compounds regulating clotting
SI1631295T1 (sl) 2003-06-06 2010-06-30 Arexis Ab Uporaba kondenziranih heterocikličnih spojin kotSCCE inhibitorjev za zdravljenje kožnih bolezni
TWI419884B (zh) 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物
SI3097085T1 (sl) * 2014-01-23 2020-11-30 Sixera Pharma Ab Derivati benzoksazinona za zdravljenje kožnih bolezni

Also Published As

Publication number Publication date
RS60830B1 (sr) 2020-10-30
JP2017503798A (ja) 2017-02-02
HRP20201500T1 (hr) 2020-12-25
US20170267692A1 (en) 2017-09-21
HUE051296T2 (hu) 2021-03-01
US10072024B2 (en) 2018-09-11
WO2015112081A1 (en) 2015-07-30
AU2015209761B2 (en) 2018-11-29
EP3097085B1 (en) 2020-07-29
PL3097085T3 (pl) 2021-01-11
PT3097085T (pt) 2020-10-08
US9695194B2 (en) 2017-07-04
CN106132941B (zh) 2018-04-06
AU2015209761A1 (en) 2016-07-07
JP6448651B2 (ja) 2019-01-09
US20170002021A1 (en) 2017-01-05
ES2820868T3 (es) 2021-04-22
SI3097085T1 (sl) 2020-11-30
EP3097085A1 (en) 2016-11-30
SMT202000557T1 (it) 2020-11-10
EP3097085A4 (en) 2017-08-09
CA2934025A1 (en) 2015-07-30
LT3097085T (lt) 2020-10-12
DK3097085T3 (da) 2020-10-26
CY1123477T1 (el) 2022-03-24
CN106132941A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
CA2934025C (en) Benzoxazinone derivatives for treatment of skin diseases
Swarnakar et al. Matrix metalloproteinases in health and disease: regulation by melatonin
Chakraborti et al. Implications of calpains in health and diseases
JP2019163296A (ja) 新しいカリクレイン７阻害剤
JP2017505299A5 (enExample)
Hou et al. LJNK, an indoline-2, 3-dione-based aminopeptidase N inhibitor with promising antitumor potency
US20020099004A1 (en) Inhibition of invasive remodelling
Voegeli et al. Desquamation: it is almost all about proteases
Das et al. Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
HK1229792A1 (en) Benzoxazinone derivatives for treatment of skin diseases
HK1229792B (en) Benzoxazinone derivatives for treatment of skin diseases
DE69732784T2 (de) Inhibierung von invasiver remodulierung
Zielińska‐Przyjemska et al. Modulatory effect of chiral nonsteroidal anti‐inflammatory drugs on apoptosis of human neutrophils
Yoshioka et al. Effect of hydroxamic acid‐based matrix metalloproteinase inhibitors on human gingival cells and Porphyromonas gingivalis
JP2010209055A (ja) 医薬組成物
JP2024520154A (ja) ６－エトキシ－７－メトキシ－２－（２－メチルスルファニルフェニル）－３，１－ベンゾオキサジン－４－オンの水中油型乳剤
JP2025105263A (ja) ウロキナーゼとウロキナーゼ受容体の相互作用阻害剤
JP2011168570A (ja) 医薬組成物
Malfait et al. ADAMTS-4 AND ADAMTS-5
HK40107125A (zh) 活性抑制和/或产生抑制剂
Checler et al. ERK1-independent α-secretase cut of β-amyloid precursor protein via M1 muscarinic receptors and PKCα/ε☆
HK1229791B (zh) 新的激肽释放酶7抑制剂
HK1229791A1 (en) New kallikrein 7 inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191119

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241219

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241219

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251223